Galderma’s Restylane Fillers Receive FDA Approval

December 28, 2016

Galderma, a global medical solutions company focusing on skin health, received U.S. Food and Drug Administration (FDA) approval of two new products for the treatment of nasolabial folds, commonly known as laugh lines. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds. These scientifically advanced gels are manufactured with XpresHAn Technology, which allows for a range of flexibility and support for varied patient needs, and effective treatment for up to 12 months. “Even with current approved options, many of my patients are still looking for different solutions to treat their laugh lines,” says Steven Fagien, M.D., Boca Raton-based oculoplastic surgeon and Restylane Refyne clinical investigator. “These new products are flexible and are designed to meet different patient needs. I am excited to offer these next-generation hyaluronic acid (HA) dermal fillers in my practice.”
Read more at American Spa Magazine >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Cold Laser Therapy: The Science and Uses for Med Spas
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations